Shell Asset Management Co. Purchases New Shares in BioNTech SE (NASDAQ:BNTX)

Shell Asset Management Co. acquired a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 19,440 shares of the company's stock, valued at approximately $2,215,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Jones Financial Companies Lllp increased its position in shares of BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after purchasing an additional 246 shares during the period. Quintet Private Bank Europe S.A. increased its position in shares of BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after purchasing an additional 700 shares during the period. Allianz SE bought a new position in shares of BioNTech in the fourth quarter worth $90,000. Generali Investments CEE investicni spolecnost a.s. bought a new position in shares of BioNTech in the fourth quarter worth $137,000. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of BioNTech during the 4th quarter worth approximately $168,000. 15.52% of the stock is owned by institutional investors.

BioNTech Trading Down 0.7%

Shares of BNTX stock traded down $0.71 during trading hours on Thursday, hitting $98.38. 182,099 shares of the company were exchanged, compared to its average volume of 985,445. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a 50 day simple moving average of $97.44 and a two-hundred day simple moving average of $108.60. The firm has a market cap of $23.65 billion, a P/E ratio of -46.85 and a beta of 1.35.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter last year, the firm posted $1.90 EPS. BioNTech's revenue was down 19.5% compared to the same quarter last year. Equities analysts anticipate that BioNTech SE will post -3.88 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on BNTX. Canaccord Genuity Group reiterated a "buy" rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Citigroup reaffirmed a "buy" rating and issued a $140.00 target price (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Morgan Stanley reduced their target price on BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. BMO Capital Markets raised their target price on BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $134.00 target price on shares of BioNTech in a report on Thursday. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $141.73.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.